Morphology based screening

Assessment of cytotoxic properties of chemical compounds widely used in drug screening can be accurately quantified using Celigo. Changes in cell morphology are indicative of cell health and can be used to identify potential drug candidates. The Celigo enables the rapid and label-free imaging of adherent cells in situ and quantification of morphological parameters. The brightfield image segmentation algorithm identifies cells based on their shape and classifies them into populations of similar morphology. Since these morphometric tools do not require the use of any label, cells can be re-imaged and analyzed over long periods of time and a variety of morphometric assays can be developed to identify potential drug effects. The Celigo brightfield imaging provides the following benefits:

• Rapid and label-free brightfield image acquisition and analysis
• Development of cell-based assays relying on morphometric measurements
• Identification and classification of cells based on cell shape
• Easy-to-use interface to acquire and analyze images

Morphology based screening on Celigo. Brightfield images of DU145 prostate cancer cells were segmented for either round, flat, or total cells. Cells in control wells (top) were mostly flat with a low percentage of round cells reported. Treatment with Celastrol causes cells in drug treated wells (bottom) to round up with a high percentage of round cells reported by Celigo. Images courtesy of Prof. CD. Muller, University of Strasbourg.

View Application Note
View Poster